Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs. treatment of physicianʼs choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) - Rugo, H S; Bardia, A; Marmé, F (Ann Oncol, 2022)